medigraphic.com
ISSN 1561-3062 (Digital)

2013, Número 4

<< Anterior Siguiente >>

Revista Cubana de Obstetricia y Ginecología 2013; 39 (4)


Expresión del fenotipo Duffy negativo en mujeres afrodescendientes y su relación con la preeclampsia

Estrada-Arcila L, Escobar-Hoyos J, Gómez-Giraldo L, Cadavid-Jaramillo AP, Gil-Villa AM

Idioma: Español
Referencias bibliográficas: 45
Paginas: 442-450
Archivo PDF: 94.76 Kb.


RESUMEN

La preeclampsia (PE) es una complicación del embarazo que trae consigo algunas consecuencias negativas para la madre y el feto: en la madre provoca principalmente hipertensión y proteinuria, mientras que en el feto puede presentarse trombocitopenia, alteración en el desarrollo del sistema nervioso central y circulatorio, y restricción del crecimiento intrauterino, lo cual se considera el factor de riesgo principal de muerte fetal en nacimientos producto de una PE severa. En la preeclampsia se presenta una disfunción endotelial relacionada con placentación anormal, estado de estrés oxidativo y proceso inflamatorio sistémico, que lleva a la activación de neutrófilos y monocitos. Se ha considerado a la interleucina-8 (IL-8) como un posible candidato desencadenante por ser quimioatrayente y activador de leucocitos; en la circulación sanguínea, la IL-8 se une a un receptor de quimiocina multiespecífico de alta afinidad denominado DARC, que es idéntico al antígeno del grupo sanguíneo Duffy. Este receptor regula los niveles plasmáticos de IL-8, uniéndose a esta quimiocina, pero cuando hay una mutación en la región promotora del gen se altera la expresión de DARC, lo que conlleva a que la IL-8 de los factores genéticos involucrados en la activación de los neutrófilos y de los monocitos, y por ende, en la disfunción endotelial presentada durante este síndrome hipertensivo, especialmente en la población afrodescendiente.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Duley L, Meher S, Abalos E. Management of pre-eclampsia. BMJ. 2006;332:463-8.

  2. Bell MJ. A historical overview of preeclampsia-eclampsia. J Obstet Gynecol Neonatal Nurs. 2010;39:510-8.

  3. Visser N, van Rijn BB, Rijkers GT, Franx A, Bruinse HW. Inflammatory changes in preeclampsia: current understanding of the maternal innate and adaptive immune response. Obstet Gynecol Surv. 2007;62:191-201.

  4. Clark P, Boswell F, Greer IA. The neutrophil and preeclampsia. Semin Reprod Endocrinol. 1998;16:57-64.

  5. Lusti-Narasimhan M, Chollet A, Power CA, Allet B, Proudfoot AE, Wells TN. A molecular switch of chemokine receptor selectivity. Chemical modification of the interleukin-8 Leu25 -> Cys mutant. J Biol Chem. 1996;271:3148-53.

  6. Kauma S, Takacs P, Scordalakes C, Walsh S, Green K, Peng T. Increased endothelial monocyte chemoattractant protein-1 and interleukin-8 in preeclampsia. Obstet Gynecol. 2002;100:706-14.

  7. Lezama P. Role of chemokines and its receptors in inflammation. Rev Med Vallejiana. 2006;3.

  8. Neote K, Mak JY, Kolakowski LF, Jr., Schall TJ. Functional and biochemical analysis of the cloned Duffy antigen: identity with the red blood cell chemokine receptor. Blood. 1994;84:44-52.

  9. Anselem O, Girard G, Stepanian A, Azria E, Mandelbrot L. Influence of ethnicity on the clinical and biologic expression of pre-eclampsia in the ECLAXIR study. Int J Gynaecol Obstet. 2011;115:153-6.

  10. Velzing-Aarts FV, Muskiet FA, van der Dijs FP, Duits AJ. High serum interleukin-8 levels in afro-caribbean women with pre-eclampsia. Relations with tumor necrosis factor-alpha, duffy negative phenotype and von Willebrand factor. Am J Reprod Immunol. 2002;48:319-22.

  11. Velzing-Aarts FV, Van der Dijs FP, Muskiet FA, Duits AJ. The association of pre-eclampsia with the Duffy negative phenotype in women of West African descent. BJOG. 2002;109:453-5.

  12. Meis PJ, Goldenberg RL, Mercer BM. The preterm prediction study: risk factors for indicated preterm births. Maternal-Fetal Medicine Units Network of the National Institute of Child Health and Human Development. Am J Obstet Gynecol. 1998;178:562-7.

  13. Borzychowski AM, Sargent IL, Redman CW. Inflammation and pre-eclampsia. Semin Fetal Neonatal Med. 2006;11:309-16.

  14. Bdolah Y, Karumanchi SA, Sachs BP. Recent advances in understanding of preeclampsia. Croat Med J. 2005;46:728-36.

  15. Burrows RF, Andrew M. Neonatal thrombocytopenia in the hypertensive disorders of pregnancy. Obstet Gynecol. 1990;76:234-8.

  16. Simpson LL. Maternal medical disease: risk of antepartum fetal death. Semin Perinatol. 2002;26:42-50.

  17. Roberts JM, Redman CW. Pre-eclampsia: more than pregnancy-induced hypertension. Lancet. 1993;341:1447-51.

  18. Gasim T. Gestational diabetes mellitus: maternal and perinatal outcomes in 220 saudi women. Oman Med J. 2012;27:140-4.

  19. Stamilio DM, Sehdev HM, Morgan MA, Propert K, Macones GA. Can antenatal clinical and biochemical markers predict the development of severe preeclampsia? Am J Obstet Gynecol. 2000;182:589-94.

  20. Bodnar LM, Ness RB, Harger GF, Roberts JM. Inflammation and triglycerides partially mediate the effect of prepregnancy body mass index on the risk of preeclampsia. Am J Epidemiol. 2005;162:1198-206.

  21. Arngrimsson R, Bjornsson S, Geirsson RT, Bjornsson H, Walker JJ, Snaedal G. Genetic and familial predisposition to eclampsia and pre-eclampsia in a defined population. Br J Obstet Gynaecol. 1990;97:762-9.

  22. Meekins JW, Pijnenborg R, Hanssens M, McFadyen IR, van Asshe A. A study of placental bed spiral arteries and trophoblast invasion in normal and severe pre-eclamptic pregnancies. Br J Obstet Gynaecol. 1994;101:669-74.

  23. Redman CW, Sargent IL. Placental debris, oxidative stress and pre-eclampsia. Placenta. 2000;21:597-602.

  24. Walsh SW. Maternal-placental interactions of oxidative stress and antioxidants in preeclampsia. Semin Reprod Endocrinol. 1998;16:93-104.

  25. Walsh SW. What causes endothelial cell activation in preeclamptic women? Am J Pathol. 2006;169:1104-6.

  26. Redman CW, Sacks GP, Sargent IL. Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol. 1999;180:499-506.

  27. Robertson SA, Mau VJ, Hudson SN, Tremellen KP. Cytokine-leukocyte networks and the establishment of pregnancy. Am J Reprod Immunol. 1997;37:438-42.

  28. Pridjian G, Puschett JB. Preeclampsia. Part 2: experimental and genetic considerations. Obstet Gynecol Surv. 2002;57:619-40.

  29. Zarbock A, Bishop J, Muller H. Chemokine homeostasis vs. chemokine presentation during severe acute lung injury: the other side of the Duffy antigen receptor for chemokines. Am J Physiol Lung Cell Mol Physiol. 2010;298:L462-71.

  30. Arbelaez C. Fundamentos de genética e inmunología para bancos de sangre y medicina transfusional. Medicina y laboratorio. 2009;15.

  31. Adams DH, Lloyd AR. Chemokines: leucocyte recruitment and activation cytokines. Lancet. 1997;349:490-5.

  32. Freeman DJ, McManus F, Brown EA, et al. Short- and long-term changes in plasma inflammatory markers associated with preeclampsia. Hypertension. 2004;44:708-14.

  33. Strieter R. Cytokines in innate host defense in the lung. J Clin Invest. 2002;109:699-705.

  34. Herrera S, Gomez A, Vera O. Antibody response to Plasmodium vivax antigens in Fy-negative individuals from the Colombian Pacific coast. Am J Trop Med Hyg. 2005;73:44-9.

  35. Mendis K, Sina BJ, Marchesini P. The neglected burden of plasmodium vivax malaria. Am J Trop Med Hyg. 2001;64:97-106.

  36. Lentsch AB. The Duffy antigen/receptor for chemokines (DARC) and prostate cancer. A role as clear as black and white? FASEB J. 2002;16:1093-5.

  37. Vergara C, Tsai YJ, Grant AV. Gene encoding Duffy antigen/receptor for chemokines is associated with asthma and IgE in three populations. Am J Respir Crit Care Med. 2008;178:1017-22.

  38. He W, Neil S, Kulkarni H. Duffy antigen receptor for chemokines mediates trans-infection of HIV-1 from red blood cells to target cells and affects HIV-AIDS susceptibility. Cell Host Microbe. 2008;4:52-62.

  39. Reich D, Nalls MA, Kao WH. Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene. PLoS Genet. 2009;5:e1000360.

  40. Stallmach T, Hebisch G, Joller H, Kolditz P, Engelmann M. Expression pattern of cytokines in the different compartments of the feto-maternal unit under various conditions. Reprod Fertil Dev. 1995;7:1573-80.

  41. Caughey AB, Stotland NE, Washington AE, Escobar GJ. Maternal ethnicity, paternal ethnicity, and parental ethnic discordance: predictors of preeclampsia. Obstet Gynecol. 2005;106:156-61.

  42. Tucker MJ, Berg CJ, Callaghan WM, Hsia J. The Black-White disparity in pregnancy-related mortality from 5 conditions: differences in prevalence and case-fatality rates. Am J Public Health. 2007;97:247-51.

  43. Eskenazi B, Fenster L, Sidney S. A multivariate analysis of risk factors for preeclampsia. JAMA. 1991;266:237-41.

  44. Sibai BM, Gordon T, Thom E, et al. Risk factors for preeclampsia in healthy nulliparous women: a prospective multicenter study. The National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. Am J Obstet Gynecol. 1995;172:642-8.

  45. Bryant AS, Seely EW, Cohen A, Lieberman E. Patterns of pregnancy-related hypertension in black and white women. Hypertens Pregnancy. 2005;24:281-90.




2020     |     www.medigraphic.com